BRAF and melanoma: (2016) demonstrated that the intravenous administration of SAMMSON‐specific antisense oligonucleotide in vivo in combination with BRAF inhibitor dabrafenib in a melanoma patient‐derived xenograft (PDX) significantly induced apoptosis, reducing the tumor growth, whereas the administration of dabrafenib alone only inhibited tumor growth.